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Abstract
Background: In recent decades, the incidence of oropharyngeal squamous cell carcinoma (OPSCC) has been rising
worldwide as a result of increasing oncogenic human papillomavirus (HPV) infections in the oropharynx. EZH2
is an epigenetic regulatory protein associated with tumor aggressiveness and negative survival outcomes in
several human cancers. We aimed to determine the role of EZH2 as a potential therapeutic epigenetic target
in HPV-positive and negative OPSCC.
Methods: The expression of EZH2 was measured by immunohistochemistry (IHC) and droplet digital PCR (ddPCR) in 2
HPV-positive and 2 HPV-negative cell lines. The cell lines were then cultured and treated with one of 3 EZH2 epigenetic
inhibitors (3-deazaneplanocin A, GSK-343 and EPZ005687) or DMSO (control). Following 2, 4 and 7 days of treatment,
cells were analyzed and compared by gene expression, cell survival and proliferation assays.
Results: EZH2 targeting resulted in greater inhibition of growth and survival in HPV-positive compared to HPV-negative
cells lines. The expression profile of genes important in OPSCC also differed according to HPV-positivity for Ki67, CCND1,
MET and PTEN/PIK3CA, but remained unchanged for EGFR, CDKN2A and p53.
Conclusion: Inhibition of EZH2 has anti-tumorigenic effects on OPSCC cells in culture that is more pronounced
in HPV-positive cell lines. EZH2 is a promising epigenetic target for the treatment of OPSCC.
Keywords: Epigenetics, EZH2, Histone methylation, Oropharyngeal cancer, Squamous cell carcinoma, GSK-343,
3-deazaneplanocin A, EPZ005687
Background
Epigenetic deregulation of cellular programs is a key
hallmark of human cancers [1–4]. Epigenetics relates to
any process that alters gene activity without changing the
deoxyribonucleic acid (DNA) sequence, and leads to
modifications that can be transmitted to daughter cells.
These modifications include DNA-methylation, non-coding
RNAs and a variety of histone post-translational modifica-
tions [5]. Of the later category, histone methylation has
been of particular interest for cancer research. Histone
methylation provides stable markers of gene expression,
turning genes “on” or “off” for the maintenance of specific
cell lineages [6]. Deregulation of histone methylation
results in altered tumorigenic gene expression profiles that
can be reproducibly identified for diagnostic purposes and
specifically reversed for novel cancer therapeutics [6–8].
Recent advances in cancer epigenetics are showing prom-
ising implications for the development of personalized
oncologic care [9]. In head and neck squamous cell
carcinoma, the importance of epigenetic cellular modifica-
tions has only recently become apparent.
In recent decades, the incidence of oropharyngeal
squamous cell carcinoma (OPSCC) has been increasing
worldwide as a result of oncogenic human papillomavirus
(HPV) [10, 11]. HPV-positive and HPV-negative OPSCCs
are distinct from clinical, pathological and molecular
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perspectives [12–19]. HPV-positive tumors overexpress p16
(surrogate marker of HPV–positive OPSCC), now used
clinically as a significant predictor of improved survival
[13]. Recent studies including our own work, has shown
significant epigenetic differences between HPV-positive and
HPV-negative OPSCC [20, 21]. Histone methylation has
been of particular interest, given the importance of these
modifications in other cancers. Histone H4 lysine 20
trimethylation (H4K20me3) has been shown to be lost as a
hallmark of human cancer [2], and is differentially
decreased in p16-positive OPSCC [20] The enzyme enhan-
cer of zeste homolog 2 (EZH2) is a histone methyltransfer-
ase (HMT) that acts to trimethylate lysine 27 on histone
H3 (H3K27me3) and its increased expression has been
linked to a number of malignancies. EZH2 has been
extensively studied in several cancers and has been shown
to play a significant role in the development of breast
cancer, lymphoma, gastric cancers, esophageal cancer, non
small-cell lung carcinomas, soft tissue sarcomas, salivary
gland adenoid cystic carcinoma, and head and neck carcin-
omas. In oral cavity cancers (OCSCC), elevated EZH2
expression correlates with more clinically aggressive tumors
that result in poorer survival outcomes [22]. In OPSCC,
which are molecularly and clinically distinct from OCSCC
the role of EZH2 in remains unclear, but may involve an
interaction with the HPV-E7 oncoprotein [23, 24].
Overexpression of EZH2 is correlated with advanced
disease and a poor prognosis in HNSCC [22]. This is
believed to be secondary to an inhibitory effect of EZH2
on the expression of tumor suppressor genes [25].
Therefore, EZH2 inhibition has been regarded as an
attractive drug target through the reactivation of tumor
suppressor genes We therefore aimed to investigate the
role of this epigenetic regulator as a potential therapeutic
target in OPSCC. To this end, three EZH2 inhibitors
(GSK-343, EPZ005687 and DZNeP) were investigated for
their inhibitory effects on EZH2 levels in HPV-positive
and HPV-negative HNSCC cell lines. To date, the use of
these inhibitors has not been reported in OPSCC.
Methods
Oropharyngeal carcinoma tissue
Fresh OPSCC tissues were obtained from patients
undergoing primary surgical treatment, as per an
approved University of Alberta health ethics research
protocol (Pro00016426). Tissues were collected and
stored as previously described [26].
Cell culture and drug treatment protocol
SCC-9 and SCC-104 cell lines were cultured using
recommended conditions [24]. Cells were sub-cultured
using common techniques with 0.25 % Trypsin/EDTA.
Cells subjected to drug treatments were seeded at ~
25 % confluency and allowed to settle and recover for
3 days. On the third day the cells were treated with fresh
media containing the various inhibitors, DMSO alone or
media with no additives. Cells were treated for 7 days,
with fresh media/drugs added on the third day and
harvest occurring on day 7.
Histone enrichment and western analysis
Histones were enriched from cell lysates following the
AbCam protocol “Histone extraction protocol for
western blot” (reference http://www.abcam.com/proto
cols/histone-extraction-protocol-for-western-blot).
Following incubation the tubes were briefly vortexed,
then centrifuged for 10 min at 6500 x g and 4 ° C. The
histone containing supernatant (~400 ul) was transferred
to new tubes and 100 ul of Trichloroacetic acid was
added. The tubes were vortexed briefly and incubated on
ice for 1.5 h followed by centrifugation for 15 min at
16,000 x g and 4 ° C. The supernatant was aspirated and
the pelleted protein was washed twice with -20 °C acetone
and allowed to dry with the lid open at room temperature
for 1.5 h. Pelleted histones were either stored at -20 ° C or
immediately subject to SDS-PAGE and Western blot. A
target of 5 μg of protein was used for Western blotting.
Membranes were incubated for 1 h at ambient temperature
with a 1:1000 dilution of anti-H3K27me3 primary antibody
(monoclonal mouse) in PBST + 3 % milk solution.
Membranes were washed extensively in PBST and incu-
bated in 1:5000 HRP-conjugated anti-mouse secondary
antibody (polyclonal goat) for 1 h at room temperature in
PBST + 5 % milk. Membranes were washed extensively
with PBST and treated with Amersham ECL Western Blot-
ting Detection Reagents kit (cat:28-392766, GE Healthcare).
RNA extraction, purification and ddPCR
RNA purification was performed using the RNeasy Plus
Mini Kit (Qiagen). The 20 μl of sample was homoge-
nized using the QIAshredder (Qiagen). 40 ng of RNA
was used to synthesize cDNA using the iScriptTM
Reverse Transcription Supermix for RT-qPCR (BIO-
RAD) as per the manufacturer’s protocol. Following the
reaction the cDNA was diluted with Nuclease-free H20
to 1 ng/μl and either stored at -20 °C or used directly for
ddPCR as described previously [26]. Primers/probes for
the detection of EGFR, MKi67, MET, TP53, CCND1,
PTEN, PIK3C and EEF2 were obtained from BIO-RAD,
using their recommended protocol. Reactions were set
up in a 96 well plate according to the QX200 Droplet
Generator Instruction Manual (#10031907 BIO-RAD).
Immunofluorescence
Cell lines were cultured and treated as per “Drug Treat-
ment Protocol” in 6-well cell culture plates containing
glass microscope cover slips coated with poly-L-lysine. A
standard immunohistochemistry protocol was followed as
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recommended by AbCam using the following antibody
concentrations. SCC-9 primary antibodies contained 1:100
dilutions of anti-EZH2 and 1:400 dilutions of anti-
H3K27me3. SCC-104 primary antibodies contained 1:50
dilutions of anti-EZH2 and 1:400 dilutions of anti-
H3K27me3 SCC-9 secondary antibodies contained 1:400
dilutions of anti-Rabbit-Alexa 647 and 1:400 dilutions of
anti-Mouse-Alexa 488 . SCC-104 secondary antibodies
contained 1:1000 dilutions of anti-Rabbit-Alexa 647 and
1:400 dilutions of anti-Mouse-Alexa 488 Coverslips were
mounted in ProLong Gold antifade reagent containing
DAPI (4’,6-diamidino-2-phenylindole; Invitrogen) and
imaged on an Aperio FL Scancope FL Images (12-bit)
were analyzed using Aperio ImageScope v12.2 and HALO
v1.95 with manufacturer’s algorithms..
Results
EZH2 expression in OPSCC patient tumors
As an initial step to investigate the potential role of
EZH2 in OPSCC, we compared the RNA expression of
EZH2 in a panel of randomly selected HPV+ and HPV-
patient tumor samples (Fig. 1). The EEF2 standardized
expression of EZH2 was found to vary significantly
between patients. The mean expression level of EZH2
was significantly higher in HPV+ vs HPV- tumors (p =
0.006). However, within both groups, there was a broad
range of EZH2 RNA levels. Levels of EGFR, TP53,
MKi67, CCND1, MET and PTEN/PIK3C were correlated
to EZH2 levels in these patient tissues. Significant posi-
tive correlations were seen between elevated EZH2 levels
and TP53 (r = 0.58) and MKi67 (r = 0.69).
Inhibition of EZH2 in HNSCC cell lines
In HNSCC cell lines, significant reductions in
H3K27me3 (EZH2 substrate) were seen on western blots
in response to epigenetic inhibitors, with differences
seen between HPV+ and HPV- cells (Fig. 2). However,
no appreciable reductions in H3K27me3 could be seen
with EPZ5687, comparable to DMSO or untreated cells.
In SCC104 cells, GSK343 treatment caused the greatest
relative reduction in H3K27me3, with no measurable
changes resulting from DZNeP or EPZ5687, even at
drug concentrations >2x higher than recommended by
the manufacturer. In SCC9 cells, GSK343 treatment also
caused a similar reduction in H3K27me3 levels, with a
slight reduction from DZNeP.
We examined the expression of EZH2 and H3K27me3
in SCC9 and SCC104 cells in response to epigenetic in-
hibitors by immunofluorescence microscopy and quanti-
tative imaging analysis. In SCC9 cells, GSK343 resulted
in a >58.3 % reduction in EZH2 positive nuclei (com-
pared to control intensity) with a slight reduction in
Fig. 1 EZH2 expression in HPV+ and HPV- oropharyngeal cancer patients. a EZH2 RNA expression from tissue biopsies in HPV+ and HPV- oropharyngeal
patient tissues measured by ddPCR absolute levels relative to EEF2 (EZH2:EEF2 ratio). Significant differences are seen between HPV+ and
HPV- patients (p = 0.006). HPV positivity was determined by clinical p16 immunohistochemistry and confirmed by HPV-16 E6 and E7 ddPCR.
b Pearson correlation of EZH2 expression in each patient tissue above with EGFR, TP53, MKI67, CCND1, MET and PTEN/PIK3C
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H3K27me3 levels (3.4 %) (Fig. 3a). EPZ 5687 did not ap-
pear to have a notable impact on EZH2 or H3K27me3
levels. DZNeP treated SCC9 cells had a minimal reduc-
tion in EZH2 positive nuclei with a ~ 25 % reduction in
H3K27me3. In SCC104 cells, GSK343 reduced the
amount of EZH2 positive nuclei by ~ 20 % while cause a
near complete reduction in H3K27me3 levels (Fig. 3a).
Although EPZ5687 and DZNeP showed a greater reduc-
tion in EZH2 positive nuclei, this resulted in a minimal
reduction in H3K27me3.
Fluorescence quantification of nuclei enabled for a
comparison of cell counts between treated and untreated
cells, providing an estimate of cell death. In SCC9 cells,
GSK 343 and DZNeP treated cells had ~ 10 % reduction
in cell counts, whereas EPZ5687 treated cells had ~ 25 %
reduction (Fig. 3a). In SCC104 cells, all three inhibitors
reduced cell counts by ~ 40 % (Fig. 3b).
Discussion
This is the first study to investigate EZH2 inhibition as a
potential epigenetic chemotherapy for OPSCC. As with
OCSCC [25], we have shown that the expression of
EZH2 is variable between patients with OPSCC but
more often elevated in HPV +OPSCC. With the rising
incidence of HPV+ OPSCC [27], the identification of
novel chemotherapeutics for this disease is becoming
ever more important. Our comparison or three EZH2
inhibitors as such potential novel therapeutic agents has
identified GSK-343 as an effective inhibitor of EZH2 and
its substrate H3K27me3 in both HPV+ and HPV- cell
lines. GSK-343 has also been recently reported to be an
effective growth suppressor in HPV+ cervical cancer cell
lines. Importantly, this competitive inhibitor of EZH2
has been shown to highly selective at exceedingly low
Fig. 2 H3K27me3 levels in HPV positive and negative HNSCC cell
lines treated with EZH2 inhibitors. Western blot of H3K27me3 levels
from of histone extrations (TCA precipitated) in SCC 104 cells (top)
and SCC 9 cells (bottom) following 7 days of growth post-treatment
with increasing concentrations of drug as shown. Coomasie stain is
shown below each blot demonstrating equal protein loading
Fig. 3 Immunofluorescence analysis of HPV positive and negative cells treated with EZH2 inhibitors. a SCC9 and b SCC104 cells processed for
immunofluorescence with DAPI, H3K27me3 and EZH2 7 days post treatment with GSK 343 (0.5 uM), EPZ5687 (5uM) or DZNeP (1uM) or DMSO
(untreated) were imaged and quantified using HALO. Cell counts are shown relative to untreated cells at day 7
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concentrations, [28] with a significantly higher affinity
for EZH2 than EPZ5687 [29, 30]. GSK-343 is therefore a
promising novel therapeutic drug warranting further
investigation for use in HPV +OPSCC.
Epigenetic aberrancies involving histone methylation are
a hallmark of human cancers [2, 5, 31–34]. Histone methyl-
transferases, the enzymes that add methylation to histones,
are central regulators of gene expression that are often
altered in human malignancies. Because of their specific
catalytic activity that can be targeted, these enzymes have
been of tremendous interest for the development of novel
chemotherapies [7, 33–38]. The histone methyltransferase
EZH2 catalyzes H3K27 trimethylation, leading to transcrip-
tional inactivation of target genes [22]. Overexpression of
EZH2 has been shown to have an important role in various
malignancies, including breast, prostate, gastric, hepatic,
and bladder carcinoma [16]. Studies examining the role of
EZH2 overexpression in HNSCC have been largely limited
to OCSCC. Zhong et.al, demonstrated a statistically signifi-
cant correlation between the overexpression of EZH2 and
tumor proliferation, pathologic grade and nodal metastases
in patients with oral tongue cancer. EZH2 has also been
shown serve as an independent prognostic marker for over-
all survival in patients with OCSCC, with high EZH2
expression being significantly associated with poorer
survival outcomes [22]. In OPSCC, which is molecularly
and clinically distinct from OCSCC the role of EZH2 in
remains unclear but may involve an interaction with the
HPV-E7 oncoprotein [22, 23]. In this study, high levels of
EZH2 were more often found in HPV+ OPSCC tumors. In
HPV+ OPSCC cell lines, inhibition of EZH2 caused a dra-
matic reduction in H3K27me3 and significant depletion in
cell counts. Our results suggest EZH2 has a central regula-
tory role in HPV+ OPSCC.
Human papillomavirus (HPV) has been identified as
an additional independent risk factor for the develop-
ment of HNSCC, particularly OPSCC. HPV-positive
and HPV-negative OPSCCs are distinct molecular and
clinical entities and have different causes, risk-factor
profiles, and survival outcomes [39]. The malignant
phenotype of HPV-positive cancer cells is maintained
by the activity of the viral E6 and E7 genes. Viral E7
activates EZH2 in cervical cancer cells and is believed
to contribute to the apoptotic resistance of HPV-
transformed cells. It also believed that EZH2 expres-
sion may be necessary for the proliferation of HPV-
positive tumor cells by stimulation cell cycle progres-
sion at the G1-S junction [23]. Our data demonstrate
that the expression level of EZH2 was significantly
higher in HPV+ vs. HPV- tumors (p = 0.006) (Fig. 1),
consistent with the results reported for HPV+ cervical
cancer [23]. EZH2 expression was found to be signifi-
cantly associated with Ki-67 expression as also noted
in overexpression of EZH2 in OCSCC [18]. Given the
association of high EZH2 levels with Ki67 seen here,
we hypothesize EZH2 may have a function in cell pro-
liferation in HPV + OPSCC.
Accumulating evidence has indicated that EZH2 serves
as an essential oncogenic driving force during the initi-
ation and progression of head neck cancers. However,
the exact expression patterns of EZH2 and associated
molecular mechanisms underlying head and neck
tumorigenesis remains to be elucidated. Normal EZH2-
mediated histone methylation process involves several
key steps. One of these steps is the binding of the cofac-
tor S-adenosyl-L-methionine (SAM) to the SAM-
binding pocket in the SET-domain of EZH2 [40]. SAM,
a methyl donor, is required for the catalytic reaction of
HMTs, including EZH2. SAM is subsequently converted
to S-adenosyl-L-homocysteine (SAH) after methyl trans-
fer to H3K27. Finally, SAH-hydrolase catalyzes the
conversion of SAH into adenosine and homocysteine.
Homocysteine can then be converted back to methio-
nine and used to generate SAM [40].
Because EZH2 is a central regulator of proliferation,
migration, invasion, and stem cell properties of cancer
cells, it is an appealing potential target for inhibition
[29]. Numerous small-molecule EZH2 inhibitors have
therefore been developed in recent years. The most
commonly described EZH2 inhibitors are the SAH-
hydrolase inhibitors, such as 3-Deazaneplanocin A
(DZNep), and the SAM-competitive inhibitor, such as
GSK343 and EPZ5687. DZNep is believed to deplete
EZH2 by proteasome-mediated protein degradation,
while GSK343 and EPZ00568 directly inhibit the EZH2
enzyme activity through competing with the co-factor
SAM. In OCSCC, treatment with DZNep reduced EZH2
protein levels in a time- dependent and dose-dependent
manner and repressed H3K27 trimethylation. Interest-
ingly, several studies have demonstrated no significant
difference in the concentration of EZH2 mRNA in the
presence of DZNep and a remarkable loss of inhibitory
effect of DZNep on EZH2 protein when cancer cells are
treated with both DZNep and a proteosome inhibitor
[30]. In our study, we have shown relatively minimal
depletion of the EZH2 substrate H3K27me3 in HPV-
cells, with a decrease in EZH2 but no measurable
decrease in H3K27me3 in HPV+ cells. When combining
data from western blots and immunofluorescence, GSK-
343 appears to be a more effective EZH2 inhibitor than
DZNeP and EPZ5687.
Although results of this study are promising for
future investigation EZH2 inhibitors in OPSCC, we
acknowledge a number of limitations. Experiments
were performed in vitro on two cell lines. Further ex-
periments with additional HPV+ and HPV- cell lines,
in addition to primary cultures and in vivo models
such as tumor explants would be important to further
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characterize the EZH2 inhibitors used in this study.
The expression of EZH2 in patient tumors was
performed on a relatively small sample size. Further
analysis of EZH2 expression in a larger cohort of
OPSCC tumors in relation to patient outcomes may
provide important information about the role of this
protein in OPSCC.
Conclusions
Inhibition of EZH2 has anti-tumorigenic effects on
OPSCC cells in culture that is more pronounced in
HPV-positive cell lines. EZH2 is a promising epigenetic
target for the treatment of OPSCC.
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